仁度生物的前世今生：2025年三季营收1.19亿低于行业均值，净利润701.37万行业排名23

Core Insights - The company, established in June 2007 and listed on the Shanghai Stock Exchange in March 2022, is a leading domestic RNA precision diagnostics enterprise with a focus on molecular diagnostic reagents and instruments, leveraging SDA technology for competitive advantage [1] Financial Performance - For Q3 2025, the company reported revenue of 119 million yuan, ranking 38th in the industry, significantly lower than the top competitor's revenue of 3.428 billion yuan and the second competitor's 3.127 billion yuan, as well as below the industry average of 708 million yuan and median of 330 million yuan [2] - The main business composition includes reagent sales at 73.15 million yuan (90.04%), instrument sales at 6.89 million yuan (8.49%), and testing services at 1.19 million yuan (1.47%) [2] - The net profit for the same period was 7.01 million yuan, ranking 23rd in the industry, again trailing behind the leading competitor's net profit of 1.588 billion yuan and the second competitor's 1.205 billion yuan, as well as below the industry average of 110 million yuan and median of 26.19 million yuan [2] Financial Ratios - The company's debt-to-asset ratio for Q3 2025 was 7.25%, a decrease from 7.76% in the previous year, and significantly lower than the industry average of 18.29%, indicating lower debt pressure [3] - The gross profit margin for Q3 2025 was 77.75%, down from 80.39% year-on-year, but still well above the industry average of 56.20%, reflecting strong profitability [3] Executive Compensation - The chairman, Ju Jinliang, received a salary of 2.0472 million yuan in 2024, an increase of 54,000 yuan from 2023 [4] - The general manager, Yu Minghui, earned 1.0415 million yuan in 2024, a decrease of 684,000 yuan from the previous year [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 7.73% to 3,765, with an average holding of 10,600 circulating A-shares, up 17.83% from the previous period [5]